research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
AZD6244 treatment causes skin aging effects by depleting skin stem cells.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Table 1_Subcutaneous injection of genetically engineered exosomes for androgenic alopecia treatment.xlsx
EX104 effectively promotes hair growth and regenerates follicles in androgenetic alopecia.
research Enhancing hair regrowth using rapamycin-primed mesenchymal stem cell-derived exosomes
Rapamycin-primed exosomes can significantly boost hair regrowth.
research [Protective effects of coenzyme Q10 on the adverse reactions of anthracycline antibiotics: using double blind method--with special reference to hair loss].
Coenzyme Q10 may protect liver function but doesn't reduce hair loss from anthracycline antibiotics.
research Tratamiento con Exosomas en Alopecia Areata Difusa Refractaria en Paciente Pediátrico: Reporte de Caso
Exosome-based therapy successfully restored hair in a 14-year-old with difficult-to-treat alopecia areata.
research Evaluation of Skin Penetration of Fluorescent Dissolved Formulations Using Confocal Laser Scanning Microscopy
Moderately lipophilic dyes penetrate skin deeply, while highly hydrophobic or lipophilic dyes stay on the surface.
research Effects of vinblastine and its metabolites on nausea and alopecia associated receptors
Vinblastine and its metabolites may cause nausea and hair loss by binding to specific receptors and could lead to better chemotherapy drugs with fewer side effects.
research Multiple drugs
Some breast cancer treatments caused long-term hair loss in women, similar to a condition called alopecia areata.
research Exosomal miR-222-3p derived from dermal papilla cells inhibits melanogenesis in melanocytes by targeting SOX10 in rabbits
Exosomal miR-222-3p reduces melanin production in rabbits by targeting the SOX10 gene.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.